$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
The rigidity of the tumor-associated ECM has been identified as a significant factor in driving malignant behavior by increasing actomyosin contractility1-3. While this effect has primarily been demonstrated with breast cancer cells, matrix rigidity has been found to alter invasive properties of cells derived from a variety of cancers4-8 suggesting that tumor rigidity may play a role in other type of cancers. To penetrate cross-linked tissues during invasive migration, cancer cells utilize actin-rich adhesive protrusions known as invadopodia that localize proteinases to focally degrade the ECM9. Invadopodia are considered a hallmark of invasive cells and have been implicated in tumor cell invasion and metastasis10,11. Previous work has shown that matrix rigidity can regulate invadopodia numbers and associated ECM degradation4,12 through myosin II activity and mechanosensitive proteins12. Given the correlation between tumor density and cancer aggressiveness13,14, these results suggest a mechanism by which cancer cells may respond to rigid tumor tissues to drive invasion and metastasis through actomyosin contractility.
In vitro ECM rigidity and in vivo tissue density have been shown to regulate invasive behavior of cancer cells1,15-17. While actomyosin contractility appears to be important in this process, current studies conflict as to whether metastatic capacity is correlated to increased or decreased contractile forces6,18-20. Furthermore, it remains unknown whether these forces directly mediate invadopodia activity21. We recently found that cancer cell contractile forces were dependent on matrix rigidity and were predictive of ECM degradation by invadopodia5. These results suggest that cellular forces may play an important role in cancer progression by mediating invadopodia activity in response to the mechanical properties of the tumor microenvironment.
In order to correlate invasive and contractile properties of cancer cells5, we modified a protocol for creating PAAs with different rigidities that was previously used to investigate rigidity-dependent invadopodia activity4,12,22. By chemically crosslinking human plasma fibronectin throughout the PAAs, these modified hydrogels can be used as the basis for both invadopodia and traction force assays to ensure that cells experienced the same rigidities in both experiments5. In the invadopodia assays, the fibronectin provides a natural binding domain for gelatin to link the overlaid ECM to the PAAs to detect matrix degradation. In the traction force assays, the fibronectin provides a ligand for direct cellular adhesion to detect microsphere displacements used to calculate cellular traction forces. This method results in what we have called soft, hard, and rigid PAAs that are bound to glass bottom dishes and have elastic moduli, E, of 1,023, 7,307, and 22,692 Pa5 which span the range of mechanical properties reported for normal and cancerous tissues23.